Balyasny Asset Management
FULC icon

Balyasny Asset Management’s Fulcrum Therapeutics FULC Stock Holding History

Balyasny Asset Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.07M Buy
+400,000
New +$3.71M ﹤0.01% 1586

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Balyasny Asset Management's FULC Position: Q1 2026 in Review

Balyasny Asset Management increased its Fulcrum Therapeutics (FULC) stake by 83% in Q1 2026, buying an estimated $7.51M and bringing the position to 1,779,946 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #870.

Balyasny Asset Management first reported a position in FULC in Q4 2021 and has held it in 11 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Balyasny Asset Management held 1,779,946 shares of Fulcrum Therapeutics worth $13.7M as of Q1 2026.
  • Balyasny Asset Management bought 809,507 Fulcrum Therapeutics shares in Q1 2026, an estimated $7.51M.
  • Fulcrum Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #870 holding.
  • Balyasny Asset Management first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.